Says misjudged Flu and Covid-19 market. Says “actively evaluating” real estate footprint and plans to consolidate facilities in U.S. Says could reduce headcount by 5%-6%. Sees $30M-$50M of Savanna respiratory revenue in 2024, primarily in Q4. Expects FY24 R&D to be flat at approximately 8% of revenue. Sees FY24 adjusted EBITDA $565M-$720M. Comments taken from Q4 earnings conference call.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on QDEL:
